Recall Register

Drug recall: chlorproMAZINE Hydrochloride Tablets, USP 100 mg, Rx Only, 100 Tablets per bottle, Manufactured for: Glenmark…

Class II FDA enforcement event 95658. Recall start date: . Status in the FDA record: Ongoing.

Reason for recall, in the words of FDA

CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Glenmark Pharmaceuticals Inc., USA started this drug recall on 11 Mar 2025. The firm address in the FDA record is in Mahwah, NJ. FDA put the recall in Class II. FDA event 95658 has 1 product record. The first FDA enforcement report date is 9 Apr 2025. The record gives the status Ongoing.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Nationwide in the USA and PR

Recalling firm

Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 95658: product records
Recall numberProductQuantityClassStatusReport date
D-0309-2025chlorproMAZINE Hydrochloride Tablets, USP 100 mg, Rx Only, 100 Tablets per bottle, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-864-018160 bottlesClass IIOngoing9 Apr 2025

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2025
322
Share of these events in Class II
79%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
55

Other events of the firm

Other FDA enforcement events of Glenmark Pharmaceuticals Inc., USA
InitiatedProduct (first record)TypeClassRecords
23 Jul 2026Azelaic Acid Gel, 15%, 50 gram tubes, For Topical Use only, Rx only, Distributed by: Glenmark Pharmaceuticals Inc., USA,DrugClass II1
27 May 2026Alyacen 7/7/7, Norethindrone and Ethinyl Estradiol Tablets USP, 0.5mg/0.035mg, 0.75mg/0.035mg, 1 mg/0.0.35mg, 3 Blister DrugClass II1
30 Dec 2025Ondansetron Orally Disintegrating Tablets, USP, 4mg, 30 Tablets (3 blistercards each containing 10 tablets), Rx only, MaDrugClass II1
21 Nov 2025Bisoprolol Fumarate and Hydrochlorothiazide Tablets, USP, 2.5 mg/6.25 mg, packaged as (a) 30-count bottles, NDC-68462-87DrugClass III1
18 Nov 2025Nebivolol Tablets, 20 mg, 90 Tablets, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya PradDrugClass III1
17 Sep 2025Azelaic Acid Gel, 15%, 50 grams, For Topical Use Only, Rx only, Manufactured by: Glenmark Pharmaceuticals Limited ColvalDrugClass II1
3 Sep 2025Viorele, Desogestrel and Ethinyl Estradiol, USP, 0.15 mg/ 0.02 mg and Ethinyl Estradiol Tablets, USP, 0.01 mg, 3 BlisterDrugClass II1
8 Aug 2025Theophylline extended-release tablets 400mg, 100-count bottle, Rx only, Manufactured by: Glenmark Pharmaceuticals LimiteDrugClass II1
7 Aug 2025Carvedilol Tablets, USP, 3.125 mg, Packaged as: a)500-count bottle, NDC 68462-162-05; b) 100-count bottle, NDC 68462-162DrugClass II3
6 Aug 2025Carvedilol Tablets, USP, 12.5 mg, 500 Tablets per carton, Rx Only, Manufactured by: Glenmark Pharmaceuticals Ltd., Plot DrugClass II2

Glenmark Pharmaceuticals Inc., USA: all 55 events

Official channels

Cite this page

Recall Register. FDA enforcement event 95658. https://recallregister.com/fda/ii/95658/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
28 Sep 2026
Newest FDA report date on the register
23 Sep 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Nationwide in the USA and PR
What quantity of product is in FDA event 95658?
The FDA record gives this quantity: 8160 bottles
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2025 have the same class?
79% of the 322 drug events that started in 2025 are in Class II.